ONO-4578

🧬 Development Program Significance

ONO-4578 is an oral EP4 antagonist in Phase 2 development. The ONO-4578-08 trial tests it in combination with nivolumab (Opdivo) and chemotherapy in first-line HER2-negative advanced gastric cancer — a setting where nivolumab plus chemotherapy is already established SoC, making the EP4 addition the incremental variable under evaluation. Enrollment is complete and the primary PFS endpoint has been met; upcoming full data disclosure at ASCO 2026 is the key near-term catalyst determining whether a Phase 3 program is warranted. Ono is also evaluating ONO-4578 in colorectal cancer (Phase 1, NCT06547385), suggesting early indication expansion efforts are underway in parallel.

🏥 Medical Significance

Gastric and gastroesophageal junction cancer represents one of oncology's most significant unmet needs, with approximately 1 million new cases annually and concentrated incidence in East Asia. Five-year survival for advanced or metastatic disease remains below 10%, despite recent improvements with checkpoint inhibitor combinations. The current first-line standard for HER2-negative advanced gastric cancer — nivolumab plus chemotherapy — has improved outcomes meaningfully in CPS-high populations, but most patients still progress within a year and long-term survival remains poor. ONO-4578 targets the EP4 receptor, one of four receptors for prostaglandin E2 (PGE2), a lipid mediator produced by tumor cells that actively suppresses antitumor immunity. By blocking EP4 signaling on immune cells, ONO-4578 is designed to relieve a distinct immunosuppressive axis within the tumor microenvironment, potentially synergizing with PD-1 blockade in patients who otherwise derive limited benefit from checkpoint inhibition alone. The first-line setting represents the highest-value treatment position clinically and commercially, but also demands demonstrating incremental benefit over an already-active immunotherapy backbone — a more stringent test than placebo-controlled designs.

📊 Commercial Significance

The global gastric cancer therapeutics market is projected to reach $5–7 billion by 2030, with growth driven by novel combination regimens and expanding checkpoint inhibitor use, though the opportunity remains heavily concentrated in Asia-Pacific markets where incidence is highest. In HER2-negative advanced gastric cancer specifically, the competitive landscape is intensifying: pembrolizumab plus chemotherapy (Merck) and nivolumab plus chemotherapy (BMS) are both established in first-line, and zolbetuximab is emerging as an active agent in the CLDN18.2-positive subset, further segmenting the addressable population. The clearest path to commercial differentiation would be identifying a biomarker-defined patient subpopulation where EP4 pathway activation drives resistance to standard checkpoint inhibition — a question the ASCO 2026 data may begin to answer.